Success Metrics

Clinical Success Rate
42.9%

Based on 3 completed trials

Completion Rate
43%(3/7)
Active Trials
0(0%)
Results Posted
167%(5 trials)
Terminated
4(50%)

Phase Distribution

Ph phase_3
1
13%
Ph phase_2
5
63%
Ph phase_1
2
25%

Phase Distribution

2

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution8 total trials
Phase 1Safety & dosage
2(25.0%)
Phase 2Efficacy & side effects
5(62.5%)
Phase 3Large-scale testing
1(12.5%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

37.5%

3 of 8 finished

Non-Completion Rate

62.5%

5 ended early

Currently Active

0

trials recruiting

Total Trials

8

all time

Status Distribution
Completed(3)
Terminated(5)

Detailed Status

Terminated4
Completed3
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
8
Active
0
Success Rate
42.9%
Most Advanced
Phase 3

Trials by Phase

Phase 12 (25.0%)
Phase 25 (62.5%)
Phase 31 (12.5%)

Trials by Status

completed338%
withdrawn113%
terminated450%

Recent Activity

0 active trials
Showing 5 of 8
terminatedphase_2

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

NCT03018288
terminatedphase_2

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

NCT01814813
terminatedphase_2

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

NCT01147536
completedphase_1

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

NCT00293423
completedphase_2

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

NCT00905060
View all 8 trials

Clinical Trials (8)

Showing 8 of 8 trials
NCT03018288Phase 2

Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

Terminated
NCT01814813Phase 2

Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery

Terminated
NCT01147536Phase 2

Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of Recurrence

Terminated
NCT00293423Phase 1

GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

Completed
NCT00905060Phase 2

HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBM

Completed
NCT02452281Phase 1

Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

Withdrawn
NCT00126178Phase 3

Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney Cancer

Terminated
NCT00098085Phase 2

Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung Cancer

Completed

All 8 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
8